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Abstract 
31 P-nuclear magnetic resonance (NMR) spectra were obtained in vitro from sera of 40 healthy volunteers and 30 patients 
with acute leukemia (AL) at the time of diagnosis and repeated up to 2-13 times during therapy. All spectra consisted of 
inorganic phosphate (Pi) peak (used as a reference peak) and two peaks from phospholipids (PL): one peak due to 
phosphatidylethanolamine and sphingomyelin (PE + SM) and second peak due to phosphatidylcholine (PC). Prior to 
initiation of therapy 31p spectra of sera of patients with acute leukemia differed from spectra of sera of normal individuals. 
Peak intensities of the PL were low in relation to Pi. During therapy leading to remission, resonance from PL progressively 
increased approximately to the spectral pattern in normal sera. Contrary to that, in non-responders the intensities of the 
phospholipids peaks remained unchanged. Long-term follow-up 31p-MRS studies showed not only a good correlation 
between this 31 P-MRS evolution of sera and the response to the therapy but also showed changes in phospholipids' levels in 
the following days during and after therapy. Moreover, correlations were found between high-density lipoprotein (HDL), 
cholesterol (CHOL) and low-density lipoprotein (LDL) concentrations measured by conventional techniques and peak 
intensities of PC and of PE + SM acquired by 31p_MRS. 
Keywords: 3xP-Magnetic resonance spectroscopy in vitro; Acute leukemia; Chemotherapy 
I. Introduction 
Abbreviations: AL, acute leukemia; AMSA, amsacrine; ARA- 
C, cytarabine; BMT, bone marrow transplantation; CR, complete 
remission; CTX, cyclophosphamide; DHAD, mitoxantrone; EPI, 
epirubicin; GPC, glycerylphosphatidylcholine; GPE, glyc- 
erylphosphatidylethanolamine; L-ASPA, L-asparaginase; LPC, 
lysophosphatidylcholine; LPS, lysophosphatidylserine; 6-MP, 6- 
mercaptopurine; MRS, magnetic resonance spectroscopy; MTX, 
methotrexate; NMR, nuclear magnetic resonance; PC, phosphati- 
dylcholine; PDE, phosphodiesters; PE, phosphatidyl- 
ethanolamine; Pi, inorganic phosphate; PL, phospholipids; P1, 
plasmalogen; PME, phosphomonoesters; PR, partial remission; 
SM, sphingomyelin; TG, tioguanine; VCR, vincristine; VP-16, 
etoposide. 
* Corresponding author. Fax: +48 71 215729. 
3~p-MRS detects changes in metabolic oncentra- 
tions which accompany biological events in the pro- 
gression of cancer. These may clinically serve as 
prognostic variables. The investigations performed 
mostly in vivo in lymphomas, sarcomas, breast can- 
cer, prostate cancer, hepatomas and metastatic liver 
cancers afforded possibilites for detection of 
metabolic differences associated with treatment sensi- 
tivity and resistance. These changes may be useful to 
predict reatment response in individual patients. 31p_ 
MRS spectra of tumors are typically characterized by
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Fig. 1.3J p spectra of sera of healthy volunteers: A. Female, aged 37, area of PL - 1.85, intensities of PE + SM - 18.6%, intensities of PC 
- 47.9%. B. Male, aged 28: area of PL - 1.51, intensities of PE + SM - 15.8%, intensities of PC - 35.1%. (Pi, inorganic phosphate; PE, 
phosphatidylethanolamine; SM, sphingomyelin; PC, phosphatidylcholine). 
high levels of phospholipid metabolites phosphomo- 
noesters uch as phosphorylcholine and phosphoryl- 
ethanolamine and phosphodiesters such as glyc- 
erophosphorylcholine and glycerophosphoryleth- 
anolamine [1-3]. Changes in the 31p spectra depend 
on these metabolites which can carry information on 
Fig. 2. Acute myelomonocytic leukemia, female aged 31 well responded to therapy. Spectrum B showed a decrease in the intensities of 
all PL peaks (PE + SM, PC). On the 7th day from the initiation of chemotherapy an increase of the PC peak intensity was observed (A). 
After the 3rd cytostatic ourse the 31 P-spectrum (C) showed a change from the pathological pattern to a normal one, which has persisted 
up to the present together with a CR of disease (A, C). A. Percentages of PC peak intensity and of PE + SM peak intensity. B. The first 
31p spectrum, before therapy: area of PL, 0.95; intensities of PE + SM, 12.9%; intensities of PC, 21.9%. C. The last 31p spectrum - 
complete remission: area of PL, 2.33; intensities of PE + SM, 23.3%; intensities of PC, 57.0%. 
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tumor regression or its progression during chemo- 
and radiotherapy [4-11 ]. 
Previously described investigations of normal 
serum by 3~P-MRS in vitro have showed that the 
spectrum consist of two sets of signals - one originat- 
ing from inorganic phosphate (Pi) and a second one 
due to serum phospholipids (PL): phosphatidyl- 
choline (PC), phosphatidylethanolamine (PE), sph- 
ingomyelin (SM), lysophosphatidylcholine (LPC), 
lysophosphatidylserine (LPS), and plasmalogen (P1) 
[12-14]. 
Observations (in vitro) of 3~p spectra of sera of 
patients uffering from multiple myeloma nd malig- 
nant lymphomas howed lower level of PL before 
therapy and suggest hat the changes of phospholipid 
metabolism induced by therapy may provide prognos- 
tic indices or predictors of sensitivity and resistance 
to individual treatment regiments [ 13,14]. 
The purposes of this investigation were: (1) to 
examine whether 31 P-MRS spectra of sera of patients 
with acute leukemia (AL) show changes before and 
during treatment similarly to patients with multiple 
myeloma nd malignant lymphomas, and to find out 
• • • 3 l  possible application of P spectra of human serum to 
therapy monitoring; (2) to find out whether there also 
exists a dependence between PL metabolism, moni- 
tored by 3~p-MRS, and lipids and lipoproteins con- 
centrations in serum measured in a conventional way. 
2. Materials and methods 
volunteers and patients, were divided into two parts: 
below age of 22 (group A, younger), and above 22 
years of age (group B, older). Group A of healthy 
volunteers consists of 15 persons (median age 17; 5 
female and 10 male), group B, of 25 individuals 
(median age 35; 15 female and 10 male). Among the 
patients in group A were 8 individuals (median age 
18; 3 female, 5 male), in group B, 24 (median age 
43; 15 female and 9 male). 
Studies were done prior to therapy and repeated up 
to 2-13 times during and after treatment, within 1 to 
16 months from beginning of the disease. Measure- 
ments were also performed in five patients, who have 
achieved complete remission (CR) lasting already 
3-9 years. 
Blood samples (10 ml) were collected by venous 
puncture in fasting state. Serum was obtained by 
centrifugation (3000 r.p.m, for 20 min) and stored in 
4°C. Measurements were performed within 24 h from 
blood collection. 31p-MRS data aquisition were car- 
ried out on a AMX 300 Bruker spectrometer (7.05 T) 
with probehead type BBI 300 MHz and NMR tube 
diameter of 5 mm. The details of method used in 
investigations are described elsewhere [13,14]. 
Concentrations of lipids - -  cholesterol (CHOL), 
triglycerides (TGL), and lipoproteins - -  HDL, low- 
density lipoprotein (LDL) of serum of all individuals 
(controls and patients) were measured at the same 
time as the spectra were obtained• The methods were 
described previously [13,14]. The statistical date were 
calculated by means of Student's t-test and verified 
by analysis of variance and Tukey test. 
31p spectroscopy was performed on serum from 40 
healthy volunteers (20 female and 20 male) with the 
median age 24 (17-60), and on serum from 33 
patients with acute leukemia: myeloblastic, lympho- 
blastic, and blastic crisis of chronic granulocytic 
leukemia (18 female and 15 male) with the median 
age 46 (17-71). Persons from both groups, i.e. healthy 
3. Results 
Previous investigations [12] and our own studies 
[13,14] have showed that 31p-MRS spectra of normal 
serum consist of three peaks, including a downfield 
Fig. 3. Acute meyloblastic leukemia, female aged 59 non-responded to therapy. After initial moderate r sponse to the treatment the 
disease progressed further and consequently a decrease in the intensities ofPE + SM and PC peaks was noted (A, C); two days after the 
final NMR examination this patient died. A. Percentages of PC peak intensity and of PE + SM peak intensity. B The first 31p spectrum - 
before therapy: area of PL, 1.29; intensities ofPE + SM, 9.9%; intensities ofPC, 18.6%. C. The last 3tp spectrum, progressio morbi: area 
of PL, 0.86; intensities ofPE + SM, 7.4%; intensities ofPC, 20.8%. 
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peak due to inorganic phosphate (Pi) and two addi- 
tional upfield peaks due to phospholipids (PL): the 
upfield-most peak due to phosphatidylcholine (PC) 
and the second peak due to phosphatidylethanolamine 
and sphingomyelin (PE + SM) (Fig. 1). Because of 
the relation of the phospholipid level from the indi- 
viduals' age [15] and AL occurrence in young pa- 
tients, both groups, i.e. healthy volunteers and the 
patients, were divided into two parts dependent on 
age: < 22 years of age (group A) and > 22 years of 
age (group B). 
Prior to initiation of therapy 31p spectra of sera of 
patients with acute leukemia differed from spectra of 
sera of normal individuals. Spectra of the patients 
revealed significantly decreased peak intensities of 
PC and PE + SM. The ratio of the peak areas of PL 
to P~ in sera of healthy volunteers in group A was 
1.18 + 0.27, while in patients before treatment that 
ratio was only 0.72_ 0.12, and in group B, 1.62 ___ 
0.42, and 0.98 ___ 0.27, respectively. Quantified in a 
different manner, peak intensities from PC in sera of 
healthy volunteers of group A, accounted for 30.8% 
+ 7.7 of the total 31p signal, while in patients it was 
only 16.9% ___ 3.1 and in group B, 40.2% + 12.8 and 
21.9% ___ 6.5, respectively. Similarly, the PE + SM 
peaks in healthy volunteers (in group A) accounted 
for 12.9% + 2.9 of the total signal but only for 
9.7% ___ 1.7 in patients, while in group B, 16.4% __+ 4.8 
and 10.6% + 3.4, respectively. These values were 
significantly different from values in healthy volun- 
teers groups (P  < 0.001), except PE + SM (P < 
0.01). 
During therapy leading to remission, these ratios 
increased. The ratio of PL to P~ increased to 1.49 + 
0.52 in group A and to 1.55_+0.40 in group B. 
Percentages of peak intensities rose as follows: PE + 
SM to 14.5% ___ 4.2 - group A, 16.5% + 4.2 - group 
B, whereas PC to 31.5% _+ 10.0 and 35.0% _+ 9.4, 
respectively. At the conclusion of the treatment, re- 
suits from the responder group did not differ signifi- 
cantly from healthy volunteers. By contrast, in non- 
responding patients (only in the group B) the ratio of 
PL to P~ did not change and equaled 0.98 + 0.21, the 
percentage of peak intensity of PC did not change at 
21.9% + 5.4, and PE + SM was down to 9.4% _ 1.4. 
These values were significantly different from noted 
in healthy volunteers group (P  < 0.001). A summary 
of these data from the entire population studied is 
presented in Table 1. 
Our investigations of lipids and lipoproteins of 
sera led by means of conventional techniques showed 
a similar pattern. In patients suffering from acute 
leukemia HDL and CHOL concentrations before 
therapy were low in both groups in comparison with 
healthy volunteers. The results are presented in Table 
1. The level of HDL in group A2 was 0.45 mmol/ l  
+ 0.13 while in group A1, 1.19 mmol/1 + 0.20, in 
groups B2 i B1 were: 0.58 mmol/1 + 0.27 and 1.11 
mmol/1 + 0.37, respectively. The concentrations of
CHOL for groups A2 and A1 were 3.26 mmol/1 ___ 0.5 
and 3.92 mmol/1 + 0.59, respectively. In older groups 
were 3.62 mmol/1 _+ 0.99 and 5.02 mmol/ l  + 0.81. 
These HDL and CHOL values increased in respond- 
ing patients and achieved the values equal or higher 
than those for healthy volunteers in the younger 
group (in groups A3 and A1 for HDL, 1.10 mmol/1 
+ 0.32. 1.19 mmol/l_+ 0.20, respectively) or only 
higher for CHOL concentration: 4.68 mmol/1 + 0.53 
and 3.92 mmol/1 + 0.59 respectively. However, in 
the older group mean concentration of lipid and 
lipoproteins increased but did not achieve a normal 
level (the values of HDL in groups B3 and B1 are: 
0.88 mmol/1 _+ 0.3, 1.11 mmol/1 _+ 0.37, respec- 
tively; for CHOL 4.17 mmol / l+  1.3 and 5.02 
mmol/l___ 0.81. In patients not responding to the 
therapy HDL, LDL and CHOL values were lower 
Fig. 4. Acute myelomonocytic leukemia, male, aged 28 for whom were performed 13 spectra from the time of diagnosis to the 
achievement of CR (A). Spectrum acquired on 5th day of cytostatic treatment pointed out on significant increase of intensities of all PL 
peaks (i.e., PE + SM and PC) resulted from direct action of ARA-C. Repeated increase of the intensities of peaks mentioned above was 
observed on 14th day from the beginning of cytostatic ourse, i.e., at the time of the most intense action of the second drug used 
(DAHD). The latter was associated with clinical and laboratory symptoms of myelosuppression. The intensities of PC and PE + SM 
decreased before the second cytostatic ourse, in spite of normal test of blood and bone marrow. Immediately after next chemotherapy 
those values consequently increased, but on the 95th day was observed a spontaneous increase of both intensities that connected with the 
achievement of CR. A. Percentages of PC peak intensity and of PE + SM peak intensity during the 13 measurements. B. The first 31p 
spectrum - before therapy: area of PL, 0.56; intensities of PE + SM, 5.8%; intensities of PC, 12.2%. C. The last 3~ p spectrum - complete 
remission: area of PL, 1.21; intensities of PE + SM, 12.5%; intensities of PC, 27.8%. 
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Fig. 6. 31p spectra of sera of patients with acute lymphoblastic leukemia who have achieved complete remission before the year 1991 and 
1986, respectively. Those spectra were similar to the spectra of healthy volunteers. A - female, aged 22: area of PL - 1.73, intensities of 
PE + SM - 15.4%, intensities of PC - 38.7%. B - male, aged 37: area of PL - 2.02, intensities of PE + SM - 22.8%, intensities of PC - 
41.0%. 
Fig. 5. Acute lymphoblastic leukemia, male, aged 18. The intensities of PC and PE + SM peaks were achieved uring 9 measurements. 
After an appreciable increase in the intensities of all PL peaks (PE + SM, PC) immediately after the remission induction chemotherapy, 
values of peak intensities decreased although the leukemia could no longer be detected in the blood or bone marrow. Only the last 
investigation before bone marrow transplantation (BMT) (22 days after last chemotherapy), showed a spontaneous increase of peak 
intensities. Two measurements performed after BMT, during CR of disease, revealed strongly increased PC peak intensity; PE + SM peak 
intensity also increased, however, after initial lowering. A. Percentages of PC peak intensity and of PE + SM peak intensity during the 7 
measurement before, and 2 after bone marrow transplantation. B. The first 3Jp spectrum - before therapy: area of PL, 0.57; intensities of 
PE + SM, 7.0%; intensities of PC, 14.2%. C. The last 31p spectrum - complete remission: area of PL, 1.11; intensities of PE + SM, 
11.2%; intensities of PC, 27.4%. 
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(0.47 mmol/1 + 0.18, 2.10 mmol/1 + 0.46, 3.22 
mmol/1 + 0.57, respectively) than those before ther- 
apy (1.11 mmol/1 + 0.37, 3.29 mmol/1 _+ 0.73, 5.02 
mmol/1 _+ 0.81, respectively). Moreover, statistically 
significant correlations were found between HDL 
concentrations and the intensities of the peaks of PC, 
of PE + SM and the area of PL measured by 31p-MRS 
(correlation coefficient: 0.58, 0.44, 0.42, respectively; 
P < 0.001). Correlations were also seen between total 
intensity of PL peaks and concentrations of CHOL, 
LDH, and HDL (correlation coefficient 0.55, 0.49, 
and 0.42, respectively; P < 0.001) and between LDL 
concentration an mentioned parameters of 31p-MRS 
(correlation coefficient 0.36, 0.40 and 0.49 respec- 
tively; P < 0.001). No correlations were found be- 
tween the parameters measured by means of 3~p-MRS 
and concentrations of TGL in serum. 
Figs. 2-5 show time-course of changes in intensi- 
ties of PE + SM and PC peaks from 31p-MRS spectra 
of sera in several patients during chemotherapy.The 
detailed escription is given in the figure caption. It 
is worth noting the good dependencies between spec- 
tra parameters and clinical stages of patients respond- 
ing or non-responding to therapy. 
4. Discussion 
MRS permits to perform an examination of 
metabolic haracteristics of human cancers cells in a 
clinical environment both in vivo and in vitro. Acces- 
sible 31p-nuclei contain information about energy 
status (phosphocreatine, inorganic phosphate, nucleo- 
side triphosphates), phospholipid metabolites (phos- 
phomonoesters, PME, and phosphodiesters, PDE), 
intracellular pH, and free cellular magnesium concen- 
tration. PME largely consist of phosphorylcholine 
and phosphorylethanolamine which are anabolic pre- 
cursors of membrane phospholipids, and PDE largely 
consist of glycerylphosphorylcholine and glyc- 
erylphosphorylethanolamine which are breakdown 
products of phospholipid metabolism [ 1-4,16-19]. 
Most cancer cells investigated by 31p-MRS [1-4] 
have high levels of phospholipid metabolites (PME, 
PDE). Contrary to that, immunodiffusion methods, 
separated preparation and 1H MRS revealed de- 
creased phospholipid contents in sera of cancer pa- 
tients [20-24]. Our studies concerned with 31p-MRS 
monitoring of phospholipid levels in sera of patients 
with haematological cancer diseases are preliminary 
ones and their direct comparison with results of other 
investigations is difficult because the latter refer only 
to cancer cells. 
Our previous observations of 31p spectra obtained 
from sera of patients uffering from multiple myeloma 
and malignant lymphomas uggest hat the therapy 
induced changes in concentration of phospholipid 
may provide prognostic indices or may be predictors 
of sensitivity and resistance to individual treatment 
regiments [13,14]. 
Our present serial 31p-MRS studies of sera from 
acute leukemic patients showed the possibility of 
observation of the phospholipid levels changes during 
and immediately after chemotherapy with a good 
dependence between the evolution of the MRS pa- 
rameters and response of the disease to the treatment. 
Prior to initiation of therapy, the 3~p-MRS spectra of 
sera revealed significantly decreased peak areas of 
PL and intensities of PC and of PE + SM. During 
therapy significant changes in these spectra were 
observed: (1) In responding patients the spectral pro- 
file has been changed and resemble that of normal 
serum with increased peak intensities of PC and of 
PE + SM; (2) In non-responding individuals peak 
intensities of PC and of PE + SM did not change; (3) 
Spectra of patients who have achieved complete re- 
mission lasting for 3-9 years did not differ from 
spectra of healthy volunteers (Fig. 6). 
Moreover some important observations from 31p_ 
MRS studies carried up to now are worth mentioning. 
The analysis of 3tp spectra obtained from sera of 
young patients with complete remission of AL showed 
that the spectral profiles were changed and resembled 
that of normal serum, but the intensities of PC and 
PE + SM did not achieve values typical of healthy 
volunteers (without division into age groups). A rea- 
son could be a low PL concentration i the sera of 
young people. It is known that PL level depends on 
age [15]. Therefore, volunteers and patients were 
divided according to their age: below 22 and above 
22. A statistically significant difference between the 
observed spectral parameters has been found both in 
control and patient's groups. After this partition, it 
turned out that the lower values of PC and of PE + 
SM intensities observed in the group of younger 
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patients during CR had statistically the same values 
as for age-matched controls. 
Although CR has been stated by clinical and labo- 
ratory features, 31p spectral pattern may remain nor- 
mal with slightly lowered PL intensity values. The 
cause of this phenomenon could be the residual 
leukemia, when the leukemia cell mass is reduced 
approximately to 10 9 cells and leukemia can no 
longer be detected in the blood or bone marrow, and 
the patient appears to be in CR. 
Another important conclusion is that 3~p spectrum 
has to be connected with the chemotherapy course. 
We have found that the investigation should be per- 
formed day by day during the cytostatic treatment 
and within a few days after the end of the course. It 
allows to observe changes of phospholipids 
metabolism, being a straight effect of chemotherapy. 
In the first days after cytostatic therapy the intensity 
peak of PC increases. It was not always correlated 
with a long-term response to the treatment. It seems 
that an increase in peak intensity related to PE + SM 
is a prognostic sign of positive, long-term response to 
the therapy. This dependence is difficult to explain 
without further detailed observations and investiga- 
tions. The spectra obtained on the spot after the 
cytostatic treatment may reflect he rate of changes of 
metabolism of cancer cells immediately after chemo- 
therapy, while the spectra obtained before the next 
course represent the metabolism of phospholipids in 
actual stage of the disease, a dozen or so days after 
discontinuance of the cytostatic treatment. The stage 
of illness (remission, progression or steady state) can 
be estimated by a comparison of consecutive spectra. 
Similarly to the findings of other researchers, it also 
reflects the advancement and the stage of the disease 
[1,2]. According to our present knowledge, this 
method can not be at present indiscriminately applied 
for diagnostic purposes of multiple myeloma, malig- 
nant lymphomas, and leukemia, but may be helpful in 
the monitoring of treatment of these diseases [13,14]. 
The 31p spectra evaluations during bone marrow 
suppression resulted from the cytostatic treatment 
may be of special importance for patients with acute 
leukemia, when it is not possible to make a prognosis 
on the basis of assessments done by means of con- 
ventional methods to determine whether the growth 
of bone marrow is normal or pathological. 
Serial studies resulted in good dependencies be- 
tween evolution of the MRS parameters and response 
of the disease to the therapy. In this way 3~p-MRS 
could be an important tool in future clinical monitor- 
ing, not only of patients with multiple myeloma nd 
malignant lymphomas but also with acute leukemia. 
Moreover, the analysis of serum phospholipids 
made by MRS offers a convenient and fast method 
for establishing a blood lipid profile in patients with 
acute leukemia during chemotherapy. Our observa- 
tions concerning changes in phospholipid metabolism 
in 3~p-MRS spectra were confirmed by measurements 
of lipoproteins and lipids in sera carried out by means 
of conventional techniques. We showed that the con- 
tent of lipoproteins and lipids in sera of patients with 
acute leukemia is decreased, except TGL concentra- 
tion. Mean HDL and CHOL concentrations, initially 
low before treatment, increased but did not return to 
normal values in older patients responding well to 
therapy; only in the group of young patients they 
were higher than in respective control group. In 
patients not responding to the therapy, values were 
lower than those before therapy. It reveals prominent 
disturbances of lipid metabolism in patients with 
acute leukemia. The perturbations of concentrations 
of HDL cholesterol noted during our investigations 
also in patients with multiple myeloma nd malignant 
lymphoma [ 13,14] are conformable to the statements 
of Dessi et al. [23], who studied the concentrations of 
total and HDL cholesterol in sera of 66 cases of 
different human haematological neoplasmas (malig- 
nant lymphomas, acute leukemias, multiple myeloma, 
myelofibrosis). All considered investigations revealed 
significant reduction of HDL cholesterol concentra- 
tions in sera of all patients and apparent inverse 
correlation between the levels of HDL and the sever- 
ity of the clinical type of neoplasia. 
The results of Dessi et al. concerning the levels of 
total cholesterol were largely scattered but Ginsberg 
et al. [24], in myeloproliferative disorders demon- 
strated in plasma reduced concentration of HDL as 
well cholesterol, similar to our observations concern- 
ing previously described patients with multiple lym- 
phoma and malignant lymphomas and now leukemias. 
Moreover, Dessi et al. [25,26] on different experi- 
mental models of normal and neoplastic ell prolifer- 
ation pointed out an increase of cholesterol synthesis 
accompanied by an accumulation of cholesterol esters 
in the growing tissues and by a marked reduction of 
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HDL cholesterol in the plasma compartment. Cell 
proliferation is a biological condition that requires 
large amounts of cholesterol for cell growth, since 
this molecule is essential for membranes biogenesis. 
It is then conceivable that alteration of intracellular 
cholesterol metabolism observed uring processes of 
sustained cell growth may also affect cholesterol 
distribution in the plasma. 
The comparison of lipid perturbations in patients 
with haematological diseases investigated by means 
of conventional methods and NMR spectroscopy 
pointed at statistically significant correlations be- 
tween HDL, CHOL, and LDL concentrations and 
peak intensities of PC and of PE + SM assessed by 
31p-MRS. These would prove that PC and SM are 
essential components of serum lipoproteins, espe- 
cially of HDL and LDL fractions [27]. PC strongly 
assimilates with A-I apolipoproteine, while SM, with 
A-II apolipoproteine. PC/SM ratio measured in all 
fractions of human lipoproteins had mean value of 
3:1. These ratio is also reflected in 31P-MRS spectra 
obtained from sera of investigated patients. 
The role of cell membrane in phospholipid 
metabolism has not been decided yet, despite numer- 
ous observations obtained both from cell models and 
human sera. Therefore, the analysis of serum phos- 
pholipids in patients with acute leukemias, lead be- 
fore and during chemotherapy can contribute in solv- 
ing the questions mentioned above. 
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